Skip to main content
Signal8
Launch Terminal

STRYKER CORP (SYK)

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Stryker Corporation logo

Stryker Corporation

NYSE:SYKHealthcare
-6.38%$291.86
AH$293.00+0.39%vs close
Mkt Cap$111.95B
Float347.86M
O/S383.57M
Vol
$ Vol
RVOL
Inst Own78.4%
SI1.6%
Earnings
Div Yield1.21%
Dilution
Stryker Corporation logoNYSE:SYK$291.86-6.38%
Phase Distribution
14 lead-sponsored trials·1 active·9 completed
Phase 13
Phase 21
Phase 31
Not applicable9
(17 more as collaborator)
Status Overview
Recruiting1
Completed9
Stopped1
Unknown3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

    IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe

    Breast Cancer, Lymph Node Mapping +1

    Enrollment
    152
    Start
    Jan 2019
    Primary Completion
    Aug 2020
    Completion
    Sep 2020
    NCT03200704
  • Phase 2
    Completed

    Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

    Bone morphogenetic protein 7, Placebo

    Osteoarthritis of the Knee

    Enrollment
    355
    Start
    Apr 2010
    Primary Completion
    Aug 2011
    Completion
    Aug 2011
    NCT01111045
  • Phase 1
    Completed

    A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee

    Intra-articular Injection of OP-1 to affected knee

    Osteoarthritis of the Knee

    Enrollment
    33
    Start
    Mar 2007
    Primary Completion
    -
    Completion
    Nov 2008
    NCT00456157
  • Phase 1
    Completed

    Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

    Bone morphogenetic protein 7

    Osteoarthritis of the Knee

    Enrollment
    51
    Start
    May 2010
    Primary Completion
    Oct 2011
    Completion
    Oct 2011
    NCT01133613
  • Phase 1
    Completed

    Perfusion Assessment in Laparoscopic Left Anterior Resection

    PINPOINT Endoscopic Fluorescence Imaging System

    Rectal Cancer, Colon Cancer +4

    Enrollment
    147
    Start
    May 2012
    Primary Completion
    Oct 2013
    Completion
    Nov 2013
    NCT01560377
  • Not applicable
    Terminated

    A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection

    PINPOINT, SPY Elite

    Rectal Cancer, Rectosigmoid Cancer

    Enrollment
    347
    Start
    Jan 2015
    Primary Completion
    May 2017
    Completion
    May 2017
    NCT02205307
  • Not applicable
    Completed

    A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping

    PINPOINT

    Endometrial Cancer, Uterine Cancer +1

    Enrollment
    180
    Start
    Dec 2015
    Primary Completion
    Jun 2017
    Completion
    Jun 2017
    NCT02209532
  • Not applicable
    Unknown status

    Large Head X3 Study

    Trident Acetabular X3 Insert

    Degenerative Joint Disease

    Enrollment
    120
    Start
    Jul 2010
    Primary Completion
    Dec 2011
    Completion
    Jul 2019est.
    NCT02543437
  • Not applicable
    Completed

    Navigation With X3 vs Non-Navigation With X3 Study

    Trident X3 Insert with Navigation system, Trident X3 Insert with conventional instrumentation

    Degenerative Joint Disease

    Enrollment
    49
    Start
    Apr 2015
    Primary Completion
    Mar 2017
    Completion
    Jul 2017
    NCT02543463
  • Not applicable
    Unknown status

    Flex Intramedullary Rod Study

    Flex IM rod

    Osteoarthritis of the Knee, Arthroplasty, Replacement, Knee

    Enrollment
    100
    Start
    Dec 2012
    Primary Completion
    Sep 2019est.
    Completion
    Sep 2019est.
    NCT02543489
  • Observational
    Unknown status

    Tritanium® Study in Japan

    Tritanium® cup

    Osteoarthritis, Rheumatoid Arthritis +1

    Enrollment
    50
    Start
    Jun 2015
    Primary Completion
    Mar 2020est.
    Completion
    Mar 2020est.
    NCT02552069
  • Observational
    Completed

    Scorpio Non Restricted Geometry (NRG) Study in Japan

    Scorpio NRG posterior stabilized (PS)

    Osteoarthritis, Rheumatoid Arthritis

    Enrollment
    150
    Start
    Jun 2015
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT02552082
  • Not applicable
    Completed

    Triathlon PKR Study in Japan

    Triathlon PKR

    Osteoarthritis of the Knee

    Enrollment
    63
    Start
    Jun 2013
    Primary Completion
    Sep 2018
    Completion
    Sep 2018
    NCT02552095
  • Not applicable
    Recruiting

    A Prospective, Pre-market, Multi-center Study of Insignia Hip Stem in THA to Determine Implant Survivorship and PROMS.

    Hip stem prosthesis

    Arthritis (E.G., Degenerative Joint Disease (DJD), Osteoarthritis, and Rheumatoid Arthritis (RA))

    Enrollment
    313
    Start
    Feb 2024
    Primary Completion
    Mar 2028est.
    Completion
    Dec 2028est.
    NCT06108934
Search ClinicalTrials.gov for “Stryker”